![Dominick Colangelo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dominick Colangelo
Vorstandsvorsitzender bei
VERICEL CORPORATION
Vermögen: 14 Mio $ am 31.07.2026
Profil
Mr. Dominick C.
Colangelo is an Independent Director at Trevi Therapeutics, Inc. and a President, Chief Executive Officer & Director at Vericel Corp.
He is on the Board of Directors at Trevi Therapeutics, Inc. and Vericel Corp.
Mr. Colangelo was previously employed as a President, Chief Executive Officer & Director by Fibrotix, Inc, an Executive VP-Corporate Development & Operations by Oscient Pharmaceuticals Corp., a Director-Strategy & Business Development by Eli Lilly & Co., and a Managing Director by LV Management Group, LLC.
He received his undergraduate degree from State University of New York at Buffalo and a graduate degree from Duke University School of Law.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VERICEL CORPORATION 0.61% | 06.03.2026 | 312’900 ( 0.61% ) | 14 Mio $ | 31.07.2026 |
| 03.06.2026 | 0 ( -.--% ) | - $ | 31.07.2026 |
Aktive Positionen von Dominick Colangelo
| Unternehmen | Position | Beginn |
|---|---|---|
| VERICEL CORPORATION | Vorstandsvorsitzender | 01.03.2013 |
| TREVI THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 29.06.2020 |
Ehemalige bekannte Positionen von Dominick Colangelo
| Unternehmen | Position | Ende |
|---|---|---|
Promedior, Inc.
 Promedior, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops therapeutics to treat fibrotic diseases | Vorstandsvorsitzender | 15.05.2012 |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Markets and sells products to community-based primary care physicians | Geschäftsführer | 11.12.2008 |
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures invests in companies located in the European regions and North America, primarily in the United States. The firm target companies operating in the fields of life sciences, biotechnology, medical technology and healthcare information technology sectors. It provides financing for early stage capital requirements. | Chief Investment Officer | 07.12.2005 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Ausbildung von Dominick Colangelo
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
70
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Markets and sells products to community-based primary care physicians | Commercial Services |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Vericel Corp.
 Vericel Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which manufactures and markets two advanced cell therapy products for sports medicine and severe burn care | Health Technology |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures invests in companies located in the European regions and North America, primarily in the United States. The firm target companies operating in the fields of life sciences, biotechnology, medical technology and healthcare information technology sectors. It provides financing for early stage capital requirements. | Finance |
State University of New York at Buffalo
 State University of New York at Buffalo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Promedior, Inc.
Promedior, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops therapeutics to treat fibrotic diseases | Health Technology |
Trevi Therapeutics, Inc.
 Trevi Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treatment for cough conditions | Health Technology |
Duke University School of Law
 Duke University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
